|
Periods
|
Prior to L-NMMA infusion period
|
At the end of L-NMMA infusion period
|
1 h after L-NMMA infusion period
|
P (GLM-within)
|
|---|
|
PRC(pg/ml)
|
|
Placebo
|
8.8 ± 5.3
|
7.4 ± 4.0
|
7.7 ± 4.3
|
0.610
|
|
Tolvaptan 60 mg
|
10.1 ± 5.8
|
8.9 ± 6.1
|
8.4 ± 4.9
|
|
p (GLM between)
|
0.489
| | | |
|
p (paired t-test, between)
|
0.481
|
0.312
|
0.523
| |
|
P-AngII (pg/ml)
|
|
Placebo
|
7.8 ± 3.8
|
7.4 ± 3.8
|
7.1 ± 3.1
|
0.801
|
|
Tolvaptan 60 mg
|
9.1 ± 5.9
|
8.9 ± 4.7
|
8.6 ± 4.3
|
|
p (GLM between)
|
0.327
| | | |
|
p (paired t-test, between)
|
0.377
|
0.151
|
0.261
| |
|
P- Aldo (pmol/L)
|
|
Placebo
|
125 (68; 168)
|
127 (99; 224)
|
119 (87; 224)
| |
|
Tolvaptan 60 mg
|
115 (87; 180)
|
147 (115; 205)
|
178 (108; 264)
|
|
p (Wilcoxon’s signed rank test, between)
|
0.420
|
0.433
|
0.170
|
- Data are given as mean ± SD or median with 25th and 75th percentiles in parentheses. General linear model (GLM) with repeated measures was performed for comparison within and between groups. Post-hoc Bonferoni test was used for comparison between L-NMMA infusion period (at the end of L-NMMA infusion period) vs baseline (prior to L-NMMA infusion period) and at baseline vs post infusion period (1 h after L-NMMA infusion period) vs baseline period, none of the p- values were significant. Paired t-test was performed to test differences between treatment groups
